GoodRx has partnered with Novo Nordisk to provide Ozempic and Wegovy for $499 per month to eligible self-paying patients. This partnership signifies the lowest out-of-pocket prices for these medications. GoodRx does not sell drugs but offers savings and coupons to be used at pharmacies. Demand for GLP-1 medications has surged, with a 22% increase in visitors seeking information on these treatments. GoodRx's stock has risen over 30% following this partnership announcement, indicating a positive market response to the new initiative.
"Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them," Wendy Barnes, GoodRX president and CEO, said in the press release. "By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them."
GoodRx has struck a deal with the pharmaceutical giant Novo Nordisk to sell its popular semaglutide medications, Ozempic and Wegovy, for just $499 per month to "eligible self-paying customers."
GoodRx's exclusive Ozempic and Wegovy offerings, available starting today, are the lowest out-of-pocket costs for the medications available on the market.
As of this writing, GoodRx's stock is up by more than 30% since market close.
Collection
[
|
...
]